Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension –– New analysis increases overall confidence in the ...

Data from ATH434-201 double-blind Phase 2 trial to be featured in oral session and multiple poster presentations - ...

AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced the completion of enrollment for REGENERATE MSA-101, its phase 1 clinical ...

Alterity Therapeutics (ASX:ATH) CEO Dr David Stamler presented new analyses from the phase II double-blinded ATH434-201 trial in MSA, showing positive effects on slowing disease progression and ...

Alterity Therapeutics (ATHE) announced that data from the ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy ...

At least, that is what doctors thought the first day he was in the hospital in late June.

The MS for Dwyfor Meirionnydd hosts an event at the Senedd, urging greater support for rare diseases, especially in the Welsh ...

Could an anomaly in the developing brain explain motor difficulties occurring decades later in people with rare movement ...

Exploring the condition pseudobulbar affect which GPs may only encounter once in a career at the most, partly due to ...